Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 74
Last updated 2026-04-14
Summary
This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
Conditions
- KRAS G12C Mutant Solid Tumors
- Carcinoma, Non-Small Cell Lung
- Carcinoma, Non-Small-Cell Lung
- Non-Small Cell Lung Cancer
- Non-Small Cell Lung Carcinoma
- Nonsmall Cell Lung Cancer
- Colorectal Cancer
- Colorectal Carcinoma
- Colorectal Neoplasms
- Colorectal Tumors
- Neoplasms, Colorectal
Interventions
- DRUG
-
JDQ443
KRAS G12C inhibitor, oral
- DRUG
-
trametinib
MEK inhibitor, oral
- DRUG
-
CDK4/6 inhibitor, oral
- BIOLOGICAL
-
EGFR inhibitor, intravenous
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-10-24
- Primary Completion
- 2026-07-29
- Completion
- 2026-07-30
- FDA Drug
- Yes
Countries
- United States
- Belgium
- France
- Germany
- Italy
- Singapore
- South Korea
- Spain
Study Locations
More Related Trials
-
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
NCT03574649 ·Status: WITHDRAWN ·Phase: PHASE2
-
Ladarixin With Sotorasib in Advanced NSCLC - Phase II
NCT05815186 ·Status: WITHDRAWN ·Phase: PHASE2
-
Ladarixin With Sotorasib in Advanced NSCLC
NCT05815173 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
NCT05118854 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
NCT02974725 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
NCT04622228 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery
NCT00254384 ·Status: COMPLETED ·Phase: PHASE1
-
This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
NCT07249879 ·Status: RECRUITING ·Phase: PHASE1
-
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
NCT01828112 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
NCT05789082 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
NCT06416410 ·Status: RECRUITING ·Phase: PHASE3
-
Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer
NCT00633568 ·Status: TERMINATED ·Phase: PHASE3
-
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
NCT01933932 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
NCT05400577 ·Status: WITHDRAWN ·Phase: PHASE2
-
Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer
NCT05045404 ·Status: WITHDRAWN ·Phase: PHASE2
-
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
NCT05054725 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
NCT04655976 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
NCT06731413 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
NCT04234113 ·Status: TERMINATED ·Phase: PHASE1
-
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
NCT05565378 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
NCT01102231 ·Status: COMPLETED ·Phase: PHASE2
-
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
NCT04720976 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04921358 ·Status: TERMINATED ·Phase: PHASE3
-
Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
NCT00985855 ·Status: COMPLETED ·Phase: PHASE2